An experimental broad-acting influenza vaccine elicited an immune response in a trial involving 175 participants, researchers reported in Annals of Internal Medicine, and the results potentially clear the way for a larger trial. The vaccine is designed to target parts of the virus that are not likely to mutate and are found in multiple strains, and its manufacture does not depend on eggs or cell cultures, says Olga Pleguezuelos, chief scientific officer of vaccine developer Seek.
Universal flu vaccine shows promise in small Phase II trial
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.